SarinaAnnePiha-PaulMD

Oncology • Houston, TX

Associate Professor, Phase I Fellowship Program Director

Join to view full profile

Dr. Piha-Paul is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Piha-Paul's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Baylor College of MedicineResidency, Internal Medicine, 2002 - 2006
Louisiana State University School of Medicine in New OrleansClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TN State Medical License 2024 - 2027
GA State Medical License 2024 - 2026
AL State Medical License 2025 - 2025
AZ State Medical License 2024 - 2025
LA State Medical License 2024 - 2025
MS State Medical License 2024 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2008 - 2025
WA State Medical License 2024 - 2025
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy Start of enrollment: 2008 Jan 25
Completed
Phase 1
FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies Start of enrollment: 2009 Apr 09
Completed
Phase 1
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib Start of enrollment: 2010 Jun 01
Completed
Phase 1
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Start of enrollment: 2012 Mar 16
Active, not recruiting
Phase 1
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
LDE225 for Patients With PTCH1 or SMO Mutated Tumors Start of enrollment: 2014 Feb 01
Terminated
Phase 2
BGJ398 for Patients With Tumors With FGFR Genetic Alterations Start of enrollment: 2014 Jul 24
Terminated
Phase 2
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Start of enrollment: 2017 Oct 31
Active, not recruiting
Phase 1
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors Start of enrollment: 2018 Aug 21
Completed
Phase 1
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer Start of enrollment: 2019 Jan 08
Active, not recruiting
Phase 1
Study of AMV564 in Subjects With Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Active, not recruiting
Phase 1
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer Start of enrollment: 2020 Jan 16
Completed
Phase 1
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Jun 16
Terminated
Phase 1
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors Start of enrollment: 2020 Jul 07
Recruiting
Phase 1
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT Start of enrollment: 2018 Jul 10
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of EP0031 in Patients With Advanced RET-altered Malignancies Start of enrollment: 2022 Sep 30
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Mirella Nardo, Mohamed A Gouda, Matthew J Reilley, Amadeo B Biter, Joann Lim
Journal of Immunotherapy and Precision Oncology. 2025-05-01
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, Hassan Ahmed Momin, Bulent Yilmaz
Cancer Medicine. 2025-02-01
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced sol...
Jibran Ahmed, Filip Janku, Daniel D Karp, Sarina A Piha-Paul, Apostolia M Tsimberidou
Cancer. 2025-02-01

Lectures

A phase I, first-in-human, dose-escalation and dose-expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplifi...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Results of the first-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain (BD) and extra terminal (BET) proteins, in patients (pts) with relapsed/re...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

MD Anderson Unveils Breakthrough Research Findings – February 10, 2025February 10th, 2025
Signature Trial Program Aims for Rapid Delivery of Novel TherapiesAugust 4th, 2016
SABCS: Studies Suggest Novel Targeted Therapies May Benefit Patients with Metastatic HR+/ HER2- Breast CancerDecember 8th, 2023
Join now to see all

SarinaAnnePiha-PaulMD

Dr. Piha-Paul is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.